1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977. 1:1645–1648.
2. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lew WJ, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med. 2005. 172:842–847.
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden Study. Lancet. 1997. 349:1269–1276.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997. 349:1498–1504.
5. Hansel TT, Barnes PJ. An atlas of chronic obstructive pulmonary disease COPD. 2004. 1st ed. New York: Parthenon Publishing;56–57.
6. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implication for treatment. Thorax. 2005. 60:605–609.
7. Lopes AA, Caramuru LH, Maeda NY. Endothelial dysfunction associated with chronic intravascular coagulation in secondary pulmonary hypertension. Clin Appl Thromb Hemost. 2002. 8:353–358.
8. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1998. 12:1446–1449.
9. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and IL-6 levels. Thromb Haemost. 2000. 84:210–215.
10. Ashitani J, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002. 41:181–185.
11. Kim TH, Ryu YH, Hur J, Kim SJ, Kim HS, Choi BW, et al. Evaluation of right ventricular volume and mass using retrospective cardiac multidetector computer tomography: comparison with first-pass radionuclide angiography. Eur Radiol. 2005. 15:1987–1993.
12. Park KJ, Kim HJ, Hwang SC, Lee SM, Lee YH, Hahn MH, et al. The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis. Korean J Intern Med. 1999. 14:72–77.
13. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005. 2:20–22.
14. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care. 2001. 5:286–289.
15. Presberg KW, Dincer HE. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med. 2003. 9:131–138.
16. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A level indicate of pulmonary vascular thrombosis with primary pulmonary hypertension. Circulation. 1990. 82:841–847.
17. Christ G, Graf S, Huber-Beckmann R, Zorn G, Lang I, Kneussi M, et al. Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences. Thromb Haemos. 2001. 86:557–562.
18. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost. 1994. 72:343–346.
19. Altman R, Scazziota A, Rouvier J, Gurfinkel E, Favaloro R, Perrone S, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol. 1996. 19:549–554.
20. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995. 86:4007–4024.
21. Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost. 1988. 60:372–376.